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Background: The randomized TARGIT trial comparing experimental intra-operative radiotherapy (IORT) to up to 7
weeks of daily conventional external beam radiotherapy (EBRT) recruited participants in Western Australia between
2003 and 2012. We aimed to understand preferences for this evolving radiotherapy treatment for early breast cancer
(EBC) in health professionals, and how they changed over time and in response to emerging data. Preferences for
single dose IORT or EBRT for EBC were elicited in 2004 and 2011, together with factors that may be associated with
these preferences.
Methods: Western Australian health professionals working with breast cancer patients were invited to complete
a validated, self-administered questionnaire. The questionnaire used hypothetical scenarios and trade-off
methodology to determine the maximum increase in risk of local recurrence health professionals were willing to
accept in order to have a single dose of IORT in the place of EBRT if they were faced with this decision themselves.
Results: Health professional characteristics were similar across the two time points although 2011 included a higher
number of nurse (49% vs. 36%) and allied health (10% vs. 4%) participants and a lower number of radiation
therapists (17% vs. 32% ) compared to 2004.
Health professional preferences varied, with 7.5% and 3% judging IORT unacceptable at any risk, 18% and 21%
judging IORT acceptable only if offering an equivalent risk, 56% and 59% judging IORT acceptable with a low
maximum increase in risk (1-3%) and 19% and 17% judging a high maximum increase in risk acceptable (4-5%), in
2004 and 2011 respectively. A significantly greater number of nurses accepted IORT as a treatment option in 2011.
Conclusions: Most Western Australian health professionals working with breast cancer patients are willing to
accept an increase in risk of local recurrence in order to replace EBRT with IORT in a hypothetical setting. This
finding was consistent over two time points spanning 7 years despite the duration of clinical experience with IORT
and the publication of the early clinical results of IORT in 2010. These results need to be compared with
preferences elicited from patient groups, and further investigation into the impact of personal preferences on
health professionals’ advice to patients is warranted.
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Breast cancer is the most common cancer, and the second
most common cause of cancer mortality after lung cancer
in Australian women [1]. Whole breast external beam
radiotherapy (EBRT) delivered in 25–35 daily fractions
over a period of 6–7 weeks is standard adjuvant treatment
for women undergoing breast conserving surgery for early
breast cancer [2–6]. EBRT must be delivered in a radiation
oncology facility, and may require temporary relocation for
women who are geographically isolated or unable to travel
daily. It is also inconvenient for those with family or work
commitments. In addition, EBRT has potential immediate
toxicities such as erythema, oedema and induration of the
breast and can result in skin breakdown severe enough to
require daily dressings. Potential long-term side effects in-
clude pulmonary fibrosis, cardiotoxicity, osteoradionecro-
sis, and the induction of secondary malignancies.
The recent development of Intra-Operative Radiotherapy
(IORT) has made the delivery of radiation directly to the
tissues at the site of the primary tumour possible, during a
single session either at the time of lumpectomy surgery or
shortly afterwards. IORT accurately targets the tissues that
are at highest risk of local recurrence and its efficacy is be-
ing tested in an international randomised controlled trial,
‘TARGIT’ that compares it to conventional EBRT. Results
published in 2010 suggested equivalent local control and
survival with a median follow-up of 3 years and 7 months
[7]. Updated 5 year results indicate IORT is still a non-
inferior treatment when it is delivered concurrently during
lumpectomy but rates of local recurrence when given as a
second separate procedure are 3.7% higher than EBRT in
the IORT arm (p = 0.069), making this a less preferred op-
tion, although survival was equivalent irrespective of the
timing of delivery [8]. Potential benefits of IORT in-
clude increased convenience, decreased time away from
home for country patients and the elderly and de-
creased time away from family and work for all women.
The TARGIT trial toxicity results confirm a different
spectrum of toxicities to EBRT including significantly
fewer skin toxicities but a higher risk of post-operative
seromas [7]. Cosmesis results suggest a better outcome
with IORT [9]. The first survival analysis of the TAR-
GIT trial has also shown a significantly lower number
of breast cancer related deaths for women receiving
IORT (1.4% Vs. 3.5%) [8].
With 5 year data now showing that IORT as a second
separate procedure gives lower rates of local control
than EBRT it will be important to determine whether
women and their clinicians are prepared to accept this
difference. Clinicians have an important role in helping
patients make decisions about adjuvant radiotherapy fol-
lowing breast conserving surgery. Studies have shown
that most cancer patients prefer to make decisions together
with their doctor, or even let their doctors decide on theirbehalf [10,11]. There is limited understanding of clinician at-
titudes and preferences surrounding radiotherapy choices.
The purpose of this observational study was to identify
what maximum increase in risk of local recurrence, if any,
health professionals working with breast cancer patients
would accept in order to have IORT instead of EBRT for
themselves, in a hypothetical setting. The study also aimed
to investigate potential socio-demographic and role factors
that may impact on the level of health professional accept-
ance of IORT and whether there was a difference between
the responses collected in 2004 and 2011, a period in
which experience with IORT had developed. This is the
first comprehensive investigation of health professional
preferences in a radiotherapy setting and will supplement
patient preference data currently being collected as part of
the TARGIT Trial.
Methods
In 2004 and again in 2011 over 200 medical and non-
medical health professionals working with breast cancer pa-
tients in hospitals with specialist breast units in Western
Australia were invited by mail to complete a health
professional preference questionnaire. The sampling
frames for each year were not available as predefined
lists, hence were created by the investigators using
knowledge of existing colleagues in the field of breast
cancer research and communication with managers
of large professional groups such as nurses, radiation
therapists, and research data managers. Invitees re-
ceived a participant information sheet, validated pref-
erence questionnaire and reply-paid envelope [12]. The
self-administered anonymous preference questionnaire
included three pages of written information covering
the purpose of the study, a description of the two treat-
ments being compared, two hypothetical preference
scenarios, and instructions on how to complete the
preference questions. The study had Human Research
Ethics Committee approval and return of the question-
naires was accepted as indicating consent. Given the
anonymity of the questionnaires, non-responders could not
be reminded to return their questionnaires.
The template for the preference questionnaire was de-
veloped and validated in previous studies for adjuvant
chemotherapy [12,13]. The questionnaire used the trade-
off method to determine the maximum increase in risk
of local recurrence of EBC that health professionals
judged acceptable in order to choose IORT over EBRT
[12,14–16]. “Trade-off” methodology is a validated and ac-
cepted method of determining patient preferences [15].
The trade-off method requires the respondents to con-
sider the positive and negative effects of a treatment to-
gether with the probabilities of these effects. In this way,
the trade-off method can be used to elicit preferences for
a specific treatment.
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using different hypothetical baseline risks of local recur-
rence in the setting of EBRT, socio-demographic questions
and six feedback questions about the questionnaire itself.
The preference questions asked health professionals to
choose either the baseline risk of recurrence of EBRT or an
equivalent or higher risk of recurrence in order to have the
more convenient, single dose of IORT instead of EBRT.
The preference questions in 2004 had hypothetical base-
line risks of recurrence following EBRT set at 6% and 9%
(based on local recurrence evidence found in the literature
at the time) and were increased for the IORT scenarios by
increments of 1% such that the maximum proposed in-
crease in risk to accept IORT over EBRT could be an add-
itional 5% risk of local recurrence [4,17,18]. In 2011 the
baseline risks of recurrence were modified to 3% and 6%
due to updated reports showing lower rates of recurrence
in low-risk early breast cancer patients [6,7]. The risks
were once again increased by an increment of 1%, but the
maximum proposed increase in risk to have IORT used
was 6% (not 5% as in 2004) due to the lower baselines be-
ing used. In the two hypothetical scenarios, local recur-
rence was described as not impacting on overall survival.
Statistical methods included Cronbach’s Alpha to iden-
tify whether responses between the 6% and 9% baseline
questions in 2004 were interchangeable and likewise
with the 3% and 6% baseline questions in 2011. Further
analysis was limited to the 6% baseline for each time
point to maintain comparability. Health professional ac-
ceptability of IORT was categorized into four groups;
not acceptable at all (‘never’); acceptable if risk is
‘equivalent’ to EBRT; acceptable if risk is 1-3% higher
than EBRT (‘low risk’); and acceptable if risk is 4-6%
higher than EBRT (‘high risk’).
Results from previous patient and clinician preference
studies were used to select variables to include in uni-
variable and multiple Poisson regression analysis to
identify if any significant drivers of preferences could be
found within the demographic data collected [12,14,19].
Chi2 was used to investigate if any significant differences
existed between the two time points, professional role
groups and different levels of familiarity with the two
treatments. Results were summarized by histograms and
a chart of cumulative proportions. Double-data-entry
was performed on all fields for quality assurance pur-
poses and all statistical analyses were performed using
IBM SPSS Statistics version 21 for Windows.
Results
Questionnaires were sent out to approximately 200 and
317 health professionals in 2004 and 2011 respectively.
Numbers are approximate because some centres re-
quested bulk mail outs of questionnaires to groups
such as ward nurses and clinical trial units, rather thandisclosing individual names for separate postage. It is
therefore unknown how many of the questionnaires
mailed out in bulk were actually received by a health pro-
fessional as their distribution was performed by the rele-
vant unit managers at each site. As the number of centres
involved in the use of IORT had grown between 2004 and
2011, an additional hospital was included in 2011, and
cancer ward nurses at two hospitals who were not tar-
geted in 2004 were also invited in 2011, leading to a higher
number of questionnaires sent out in that year.
In 2004, responses were received from 90 health profes-
sionals (45% return rate) and in 2011 the return rate was
35% with 110 responses received. Of those received, 80
and 92 were included for analysis in 2004 and 2011 re-
spectively. Exclusion from analysis occurred if a) partici-
pants worked less than 5% with breast cancer patients
(n = 24, 12%) b) participants had experienced radiothe-
rapy themselves (n = 1, 0.5%) or c) if responses to the
preference questions were indeterminate (n = 3, 1.5%).
Response rate data is summarized in Table 1.
Comparison of the 6% and 9% baseline questions in
2004 revealed a significant agreement on Cronbach’s
Alpha (0.963, p = <0.0001) as did the comparison of the
3% and 6% baseline questions in 2011 (Cronbach’s Alpha
0.880, p = <0.0001). As a result, all subsequent analyses
of preference responses focused only on the 6% baseline
question from each year group.
Table 2 summarizes the descriptive characteristics of
the 2004 and 2011 participants. Demographics in the
two year groups were similar, with the majority of partic-
ipants being female, having partners and dependents,
and having had a friend or relative who had experienced
radiotherapy. Differences between the two time points
included the number of radiation therapists declining
from 26 down to 16 (32% vs. 17%) and an increase in
nurses from 29 to 45 (36% vs. 49%) and allied health
professionals from 3 to 9 (4% vs. 10%) participating in
the study. Allied health professionals included data man-
agers (n = 2 and 5) and psychologists (n = 1 and 4).
The proportion of medical health professionals across the
two time points was similar, representing 28% and 24% of
the responses in 2004 and 2011 respectively. In 2004 and
2011, the medical group comprised of 7 and 9 surgeons, 6
and 3 medical oncologists, 8 and 6 radiation oncologists, 1
and 2 breast physicians and one radiologist in 2011. One
registrar with no specified specialty also responded in 2011.
Overall exploration of gender across role groups revealed a
p-value approaching significance (Fisher’s Exact Chi2 p
0.052) with a decline in number of male medical health
professionals (15 vs. 9) and a reciprocal increase in number
of female medical health professionals (7 vs. 13) from 2004
to 2011 (Fisher’s Exact Chi2 p 0.065).
Despite a larger sample size in 2011, familiarity with ei-
ther EBRT or IORT did not yield any significant differences
Table 1 Questionnaire response rates in 2004 and 2011
2004 2011
Sent out (approximate) 200 317
Received (response rate) 90 (45%) 110 (35%)
Excluded because <5%
time worked with Br Ca
9 15




Total number excluded 10 (11%) 18 (16%)
Number analysed 80
89% of those received
40% of those sent out
92
84% of those received
29% of those sent out
Table 2 Descriptive characteristics of health professionals





Female 61 (76) 80 (87)
Median age, years (range) 43.5 (24–63) 45.5 (21–67)
Role group
Medical 22 (28) 22 (24)
Radiation therapist 26 (32) 16 (17)
Nurse 29 (36) 45 (49)
Allied health 3 (4) 9 (10)
Time dedicated to working with breast
cancer (range*)
5-100 5-100
25th Percentile 20 10
50th Percentile 30 30
75th Percentile 67 60
Marital status (has partner) 61 (76) 67 (73)
Has children 54 (68) 58 (63)
Has children <15 yrs 27 (34) 30 (33)
Has dependents 51 (64) 54 (59)
Has relative/friend who died from cancer 63 (79) 81 (88)
Has relative/friend who has had
radiotherapy
55 (69) 69 (75)
Ever considered radiotherapy for themselves 2 (2.5) 2 (2.2)
Familiarity with EBRT
Never heard of it 1 (1.3) 2 (2.2)
Read or heard about it 8 (10) 18 (20)
Supervised patients having it 71 (89) 72 (78)
Familiarity with IORT
Never heard of it 7 (9) 12 (13)
Read or heard about it 36 (45) 38 (41)
Supervised patients having it 37 (46) 42 (46)
*Note that responses less than 5% were excluded from analysis as suggestive
of insufficient experience with breast cancer patients.
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supervised by 89% then 78%, and had been read or heard
about by 10% then 20% respectively. Likewise familiarity
with IORT showed little change, with 9% then 13% having
never heard or read about it, and a stable number of those
having supervised it or read/heard about it.
The actual levels of risk health professionals were will-
ing to accept in order to have IORT in place of EBRT
varied considerably (Figure 1). In both 2004 and 2011,
most health professionals were willing to accept IORT as
an alternative treatment option, with only 7.5% and 3.3%
(n = 6 and 3) respectively indicating they wouldn’t have
IORT at all (‘never’). If it offered an ‘equivalent’ risk of
recurrence, 18% and 21% (n = 14 and 19) would have it,
with a similar proportion accepting IORT if it offered a
4-6% (‘high’) increase in local recurrence (19% and 17%
with n = 15 and 16). The majority of health professionals
would accept IORT if it offered a 1-3% (‘low’) increase
in local recurrence (56% and 59% with n = 45 and 54).
Figures 2 and 3 display the similarity of responses received
across role groups in 2004 and 2011 respectively.
Figure 4, showing the cumulative increase in risk
health professionals are willing to accept in order to
have IORT in place of EBRT, further illustrates the
similarity between the two time points. This graph
suggests that approximately 60% of health profes-
sionals would accept IORT if it increased the risk of
local recurrence by 2% and approximately 40% would
accept it at an increased risk of 3%.
Chi-squared analysis of preference category by role group
revealed the only significant difference between the two
time points was in the nursing role group (Fisher’s exact p
value = 0.026). In 2004, 5 (17.2%) nurses would not have
IORT at all compared to 1 (2.5%) in 2011 and 1 (3.4%)
would have it only if it offered an equivalent risk of LR in
2004, compared to 10 (22.2%) in 2011. The proportion of
nurses accepting IORT with a low or high extra risk did
not change between the two time points (55% vs. 53% for
low risk and 24% vs. 22% for high risk). Significant differ-
ences were not found in any other role group, as illustrated
in Table 3.
Univariable and multiple Poisson regression analyses
did not identify any significant drivers of preferences in
either year group (Table 4).
Feedback from health professionals in 2004 and 2011 re-
vealed 84% found the questions clear, few thought answer-
ing the questions was hard (10% and 15%), or that the
questions were hard to understand (19% and 14%) or
stressful (6% and 5%), and most were glad that they took
part in the study (69% and 77%). Only 3.8% and 7.6% found
the questions both hard to understand and hard to answer
in 2004 and 2011 respectively. The median time for com-
pletion was 9 minutes (range 2–30) in 2004 and 8 minutes



























Figure 1 Health professional preferences.
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The few published studies that have reviewed patient pref-
erences with regards to adjuvant radiotherapy and risk of
local recurrence have been focused on the trade-off be-
tween either adjuvant radiotherapy and mastectomy, or
radiotherapy vs. no radiotherapy [20–22]. Results of one
American study conducted in the late 1990s strongly sug-
gested that the fear of a local recurrence and an actual local
recurrence leading to mastectomy have such a negative
impact on quality of life that patients are willing to accept
the risks and inconvenience of radiation therapy to avoid
them, even if there is no benefit to survival [21]. A similar
Canadian study also concluded that patients are unwilling
to accept even small increases in local recurrence risk to
avoid radiotherapy, and that clinicians underestimate the
fear that patients have for local recurrence and their desire
to use all available treatment options for small gains [22].
Investigation into health professional preferences for
chemotherapy also in the 1990s found that health profes-
sionals require larger benefits of treatment to make chemo-
therapy worthwhile compared to patients [23,24].
The historical studies described above make it clear that
the value of adjuvant treatment after conservative surgery is
dependent on how women feel about the trade-off between
the fear and consequences of a local recurrence vs. the tox-
icity and inconvenience of treatment, and that patients ap-
pear to place significant value on the local control of their
cancers in terms of their overall quality of life. Health care
professionals' attitudes and preferences may determine
what treatment options they discuss with patients, and
these may differ significantly to the attitudes and prefer-
ences of their patients. This may be particularly import-
ant when introducing new treatments or technologies
where quality of life issues are significant and there is
no survival advantage.In this study, we aimed to understand what determined
health care professionals’ preferences for IORT or EBRT
in early breast cancer. Despite the absence of any signifi-
cant determinants of preference, the 2011 data shows a
general acceptance of IORT as an alternative treatment to
EBRT across all surveyed role groups such that only 3.3%
would not accept it all, 80% would have it if it offered ei-
ther an equivalent or low (1-3%) increase in risk and 17%
would have it even if it posed a 4-6% increase in local
recurrence. The lack of any identified determinants of
preference was unexpected given findings from previous
preference studies showing at least one significant driver
of preference. A study of lung cancer health professionals
found that having a partner or having dependent children
was associated with judging smaller survival benefits
of chemotherapy sufficient [12]. Preference studies on
patient groups have similarly found having dependents
at home is a significant determinant of preference in a
chemotherapy setting [14,19]. There are no published
preference studies for health professionals in radiothe-
rapy, however the only two patient preference radiothe-
rapy studies available also did not find any significant
determinants of preference [21,25]. Of note, and similar
to the present study, neither of these studies was asses-
sing preferences in the context of survival differences. It
is possible that the socio-demographic determinants of
preferences such as having a partner or dependent chil-
dren come into effect when a survival difference is con-
sidered, but are less important when survival is not the
outcome being considered. Furthermore, factors such as
older age, employment and rural location may be hypo-
thesized as important determinants of preferences for pa-
tients considering IORT, but could not be included in the
health professional study as by definition the participants
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Figure 2 2004 Preferences by role group.
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same procedure as tumour removal, or as a separate pro-
cedure some time later, however updated results of the
TARGIT study have shown the preferred approach is to
offer IORT at the same time as tumour removal because
the differences in risk of local recurrence compared to
EBRT were found to be 1% (p = 0.31) for during initial sur-
gery and 3.7% (p = 0.069) when performed as a separate
procedure [8]. Qualitative data collected during this study
suggests that preferences for IORT may be influenced by
the timing of the procedure, as a separate procedure would
require an additional general anaesthetic. The timing of the
procedure in addition to personal characteristics in-
dependent of socio-demographics may also need to be
considered in future studies of health professional pre-
























Figure 3 2011 Preferences by role group.including examination of psychological factors such as risk
profiling, and body image.
Although designed as a simple observational cross-
sectional study, this study has several potential limitations.
The study sample size was restricted by the number of
health professionals working with breast cancer patients
in Western Australia at the two time points. The devised
sampling frames were representative of the majority of
health professionals working in breast cancer care in
Western Australia in both 2004 and 2011 however they
may have under-represented allied health staff such as
psychologists, social workers, physiotherapists and pallia-
tive care physicians as they made up less than 5% of the
sampling frame at both time points. Representative per-
centages of data managers (9% and 4%), radiation oncolo-




















Figure 4 Cumulative proportions of health professionals accepting IORT. Note: In 2004, the maximum increase in risk presented was 5%
hence there is no 2004 value for the 6% increase in risk.
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pists (21% and 20%) and radiologists (5% and 10%) were
invited in 2004 and 2011 respectively.
Observed response rates were low which is common
in surveys of health professionals, particularly if they are
anonymous [26] however the final number of partici-
pants in each year group is similar to several relevant
published preference studies [19,21,27]. The reduced re-
sponse rate in 2011 is possibly due to the reluctance of
health professionals to complete the questionnaire again
if they recalled completing it in 2004, despite the infor-
mation sheet indicating the investigators wanted them to
complete it again because “more is known about IORT
now, and it is more likely that you have been involved in
the care of patients post IORT now than when you first
completed the questionnaire six years ago”. The lite-
rature suggests that when surveying health professionals,
responder bias is modest, and less important than in
surveying patient or consumer groups [28]. However,
selection bias may exist due to targeting only health
professionals known to be working in the field in one
of four major hospitals in Western Australia. The lower
IORT familiarity scores in 2011 are possibly a direct con-
sequence of increasing the number of people asked to par-
ticipate, particularly the nursing group, as the use of IORTTable 3 Significant preference category changes
by Nurses
Preference 2004 2011
Would not have IORT at all 17% 2%
Would have IORT only if equivalent to EBRT 3% 22%
The only significant difference found between the two time points was in the
nursing group (Fishers Exact Chi2 p = 0.026 ). Differences were not found in
the medical group (p = 0.47), radiation therapist group (p = 0.95) or the allied
health group (p = 0.61).had remained relatively stable in clinical practice between
2004 and 2011.
A further potential limitation is that because the focus
of the hypothetical scenario in this study was local re-
currence, we indicated that survival was exactly the same
for both treatments. This study did not measure the
opinions of health professionals in regards to this forced
assumption of equivalent survival. Updated results of the
full TARGIT trial cohort with a median follow-up of
2.5 years have now shown that breast cancer mortality is
not different between the two treatments, although sig-
nificantly fewer non-breast cancer deaths were reported
for EBRT [8]. Longer term follow-up is needed to con-
firm these findings, as the number of events is still low.
Despite this recent finding, given the 15-year survival
data published in 2005 suggests that for every 4 local recur-
rences avoided, one life is saved, future health professional
preference studies of radiotherapy should incorporate this
information [6]. Further to this, we updated the baseline re-
currence rates in 2011 from 6% and 9% (used in 2004) to
3% and 6% to be in line with the emerging literature report-
ing lower local recurrence rates for early, low risk breast
cancer patients treated with breast conserving surgery. As
we have reported above, the change in baselines didn’t ap-
pear to affect this study however, as we used the 6% base-
lines from both years and analysis showed there wasn’t any
significant difference in the way respondents answered the
lower and upper baseline questions within each year group.
In retrospect, the reduced baselines were appropriate given
the updated TARGIT results reporting recurrence rates be-
tween 1.1% and 5.4% [8].
There is much patient preference literature available
for chemotherapy decisions, however patient preference
research for breast radiation treatment is limited and
outdated [21]. Specific research on patient preferences
Table 4 Potential drivers of preference explored with
univariable analysis
Characteristic Univariable P-value
Year 2004 2011 Combined
n = 80 n = 92 n = 172
Gender* 0.29 0.85 0.51
Age* 0.61 0.60 0.47
Marital status* 0.38 0.68 0.37
Has dependents* 0.74 0.38 0.38
Has children younger than 15* 0.82 0.19 0.26
Friend or relative died of cancer* 0.46 0.65 0.38
Role group 0.84 0.95 0.79
Medical vs. non-medical role group* 0.46 0.84 0.52
IORT Familiarity 0.87 0.98 0.94
% time working with breast cancer
patients*
0.10 0.59 0.14
Participation year - 0.85
*Overall multivariable Poisson Regression analysis included these variables
yielding an insignificant p-value of 0.685. In 2004 p = 0.850 and in
2011 p = 0.904.
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ant area to consider in anticipation of IORT becoming a
standard treatment option. With the updated results of
the TARGIT trial showing IORT offers a lower rate of
local control than EBRT when offered as a second separ-
ate procedure, it will also be important to determine
whether patients are prepared to accept this difference.
With 17% of health professionals surveyed in 2011 hypo-
thetically accepting an increased risk as high as 4-6%, it is
critical to understand which patients have similar prefer-
ence profiles. Patient preferences should be incorporated
in treatment decisions especially when life expectancy var-
ies little and quality of life considerations are prominent.
In order to inform such decisions, estimates of the max-
imum difference in tumour control rates that would be ac-
ceptable by patients are also needed.
This study has provided unique information about the
preferences of health professionals working with breast
cancer patients in regards to IORT and EBRT for early
breast cancer. The high acceptance of the question-
naire and brief time required to complete it demon-
strates that health care provider preference studies can
be implemented with minimal inconvenience to partic-
ipants and may supplement information on patient
preferences where treatment choices are available. This
study has shown that determining the preference of
health care professionals for one treatment over an-
other is a complex and individual process that cannot
be generalized to any particular professional role or
socio-demographic characteristic. This data will sup-
plement the clinical results of the TARGIT trial and
help clinicians become aware of their own preferencesfor adjuvant radiotherapy and therefore help patients
make well informed and unbiased treatment related
decisions should IORT become available as a standard
treatment option in the future.
Conclusions
The majority of Western Australian health professionals
working with breast cancer patients surveyed in 2004 and
2011 accepted IORT as an alternative treatment option to
EBRT for early breast cancer. Only 3% of health profes-
sionals surveyed in 2011 indicated they would not have
IORT at all, and 76% would accept it even if it presented
an increase in risk of recurrence. This outcome was rela-
tively consistent over two time points spanning 7 years
despite the duration of use of IORT and the publishing of
the early clinical results of IORT in 2010. These results
need to be compared with preferences elicited from pa-
tient groups, and further investigation into what drives
preferences in health professionals and how this influences
recommendations to patients is warranted.
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